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Abstract
Background: Ankyrins are cellular mediators of a number of essential protein-protein interactions. Unlike
intrabodies, ankyrins are composed of highly structured repeat modules characterized by disulfide bridge-
independent folding. Artificial ankyrin molecules, designed to target viral components, might act as intracellular
antiviral agents and contribute to the cellular immunity against viral pathogens such as HIV-1.
Results: A phage-displayed library of artificial ankyrins was constructed, and screened on a polyprotein made of
the fused matrix and capsid domains (MA-CA) of the HIV-1 Gag precursor. An ankyrin with three modules named
Ank
GAG1D4 (16.5 kDa) was isolated. Ank
GAG1D4 and MA-CA formed a protein complex with a stoichiometry of 1:1
and a dissociation constant of Kd ~1μM, and the Ank
GAG1D4 binding site was mapped to the N-terminal domain
of the CA, within residues 1-110. HIV-1 production in SupT1 cells stably expressing Ank
GAG1D4 in both N-
myristoylated and non-N-myristoylated versions was significantly reduced compared to control cells. Ank
GAG1D4
expression also reduced the production of MLV, a phylogenetically distant retrovirus. The Ank
GAG1D4-mediated
antiviral effect on HIV-1 was found to occur at post-integration steps, but did not involve the Gag precursor
processing or cellular trafficking. Our data suggested that the lower HIV-1 progeny yields resulted from the
negative interference of Ank
GAG1D4-CA with the Gag assembly and budding pathway.
Conclusions: The resistance of Ank
GAG1D4-expressing cells to HIV-1 suggested that the CA-targeted ankyrin
Ank
GAG1D4 could serve as a protein platform for the design of a novel class of intracellular inhibitors of HIV-1
assembly based on ankyrin-repeat modules.
Keywords: HIV-1, HIV-1 assembly, Gag polyprotein, CA domain, virus assembly inhibitor, ankyrins, artificial ankyrin
library, intracellular antiviral agent
Background
In recent years, significant progress has been made in
the control of HIV-1 infections using highly active anti-
retroviral therapy (HAART). Nevertheless, the occur-
rence of multi-drug resistant mutants and the side
effects of HAART justify the exploration of alternative
therapeutic approaches, such as gene therapy [1-5].
Several strategies for anti-HIV gene therapy are cur-
rently under development, and certain ones have been
tested in hematopoietic cells [6-8]. They can be classi-
fied into two major categories: (i) RNA-based agents
including antisense, ribozymes, aptamers and RNA
interference [9]; (ii) protein-based agents including
dominant-negative mutant proteins, intrabodies, intra-
kines, fusion inhibitors and zinc-finger nucleases [10,11].
The most commonly transduced genes with antiviral
potential consist of those encoding derivatives of immu-
noglobulins. However, the complex structure of these
molecules limits their antiviral function within cells,
since their stability relies on disulfide bond(s) which
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cellular milieu [12-16].
Several methods and novel molecules have been devel-
oped to overcome the limitations of antibodies and their
derivatives (e.g. scFv), in terms of stability, facility of
modifications, robustness, and cost-efficient production
[13,17-19]. This is the case for molecules based on pro-
tein frameworks or scaffolds which interact with poten-
tial therapeutic targets by mimicking the binding
process of immunoglobulins to their specific antigens.
The ankyrin-repeat proteins represent an attractive scaf-
fold to generate this type of specific binders [20,21].
Analysis of the protein sequence-structure relationship
in natural ankyrins has defined consensus ankyrin motifs
(or modules), and the results have been used to generate
large libraries of artificial proteins, called ‘Designed
Ankyrin-Repeat Proteins’ or DARPins. Several DARPins
with desired binding specificity to various target mole-
cules have successfully been isolated from such libraries
[12,21-27], including competitors of HIV-1 binding to
the viral receptor CD4 [28].
Ankyrins mediate many important protein-protein
interactions in virtually all species and are found in all
cellular compartments, indicating that these proteins
can be adapted to function in a variety of environments,
intracellular as well as extracellular
[12,20,21,23,25,29,30]. For example, lentiviral vectors
pseudotyped with HER2/neu-specific DARPins have
been found to efficiently transduce their specific targets,
HER2/neu-positive cells [31]. The major advantages of
ankyrin-repeat proteins reside in (i) their binding speci-
ficity and affinity, as observed in DARPins selected from
large libraries; (ii) their solubility and stability, even in
the reducing conditions of the intracellular milieu; (iii)
their sequence features present in DARPins, which are
naturally expressed in human cells: as a consequence,
ankyrin-repeat proteins are expected not to be as immu-
nogenic as foreign proteins. Artificial ankyrins are there-
fore promising candidates as protein interfering reagents
capable of acting both extra- and intra- cellularly [24].
In the present study, we designed artificial ankyrin
molecules targeted to the HIV-1 Gag polyprotein and
evaluated their potential as intracellular therapeutic
agents which would negatively interfere with HIV-1
replication, and more specifically with the virus particle
assembly machinery. To this aim, we constructed a
library of ankyrin-repeat protein library expressed at the
surface of recombinant filamentous bacteriophages. This
phage-displayed library was screened on immobilized
matrix (MA)-capsid (CA) domain (MA-CA) of the HIV-
1 Gag precursor (Pr55Gag, or more simply Gag), and a
panel of Gag-specific artificial ankyrins were isolated.
One particular Gag binder, Ank
GAG1D4, was selected
for further characterization. Ank
GAG1D4 binding site
was mapped to the N-terminal domain of the CA, and
SupT1 cells that stably expressed Ank
GAG1D4 showed a
reduced permissiveness to HIV-1 infection. The
Ank
GAG1D4-mediated antiviral effect was found to
occur at post-integration steps of the HIV-1 life cycle
involving the Gag protein assembly and budding
machinery. This study demonstrated the potential of
ankyrin-repeat proteins as a novel class of intracellular
antivirals and suggested that Ank
GAG1D4 could serve as
a protein platform for the design of efficient intracellular
inhibitors of HIV-1 assembly.
Results
Design of artificial ankyrin-repeat motifs and construction
of an ankyrin library
The construction of an artificial ankyrin library implies
the randomization of amino acid residues localized on
the accessible surface of ankyrin which has a potential
interaction with the desired target, while maintaining
intact the conserved residues of the consensus repeat
modules which form the rigid framework of ankyrin.
The consensus sequence of the ankyrin-repeat modules
generated in this study was based on previous DARPins
libraries [12-14,23,29,30,32], with minor modifications,
as described in the Materials and Methods section. For
example, the lysine residue (K) at position 25 was sub-
stituted for glutamate (E) to prevent a possible repulsion
with the positively charged arginine (R) at position 21
(Tables 1 and 2). Our ankyrin library was generated by
randomization of amino acids at positions 2, 3, 5, 10,
13, and 14 (Figure 1 and 2). The amino acid side chains
at these positions were all oriented outwards and
belonged to the same surface-exposed surface of the
ankyrin-repeat module (Figure 2B).
The artificial ankyrin-repeat proteins obtained were
made of a variable number of ankyrin modules flanked
by N- and C-capping sequences (N-cap and C-cap; Fig-
ure 1B). The library was generated using the directional
polymerization of one ankyrin microgene, each micro-
gene corresponding to one single repeat motif. Polymer-
ization was realized directly into a phagemid vector [33].
This resulted in proteins with variable numbers of
repeats and sequence lengths. The length distribution in
the library was determined by digesting the phagemid
pool with restriction enzymes whose sites were located
on both sides of the ankyrin coding sequence, followed
by analysis of the DNA fragments by gel electrophoresis.
A maximum number of 15 ankyrin repeats was
obtained, and the most frequent numbers ranged from 1
to 6.
Our final phage-displayed ankyrin library represented
as many as 1.9 × 10
8 independent clones. The quality of
our library was first evaluated by sequencing proteins
from randomly picked clones. Nine out of fifteen clones
Nangola et al. Retrovirology 2012, 9:17
http://www.retrovirology.com/content/9/1/17
Page 2 of 27(60%) presented discontinuous sequences, with sequence
frameshifts and stop codons, which likely resulted from
errors in oligonucleotide synthesis and/or assembly. Dis-
continuous sequences occurred with a higher frequency
in ankyrins with numerous modules, while most ankyrin
molecules with fewer repeats showed correct, open read-
ing frames. The proportion of clones in our library with
readthrough ankyrin sequences was also evaluated from
the proportion of colonies which expressed C-terminally
His-tagged soluble ankyrin protein: 34% (24 out of 72
clones) were found to be positive for the C-terminal
His-tag, as monitored by colony filtration blotting
(COFI blot; data not shown). We therefore estimated
the real diversity of our library to one third of the total
number of independent clones, i.e. 6 × 10
7 independent
ankyrin coding sequences.
Production and purification of the viral protein target:
HIV-1 Gag precursor H6MA-CA
The viral target used for screening our phage-displayed
ankyrins consisted of the His-tagged recombinant
polyprotein H6MA-CA, corresponding to the MAp17
and CAp24 domains of the HIV-1 Gag precursor. The
rationale for screening our ankyrin library on the MA-
CA target was not only to search for MA- or/and CA-
binders, but also for ankyrin(s) which recognize(s) the
MAp17-CAp24 hinge region, which contains the clea-
vage site of the viral protease (PR). His-tagged recombi-
nant protein H6CA, which corresponded to the mature
capsid protein CAp24, was used to identify the struc-
tural domains of the Gag precursor which contained the
ankyrin-binding site. Large amounts of recombinant
H6MA-CA and H6CA proteins were produced in Sf9
cells infected with recombinant baculoviruses BV-
H6MA-CA or BV-H6CA, and the recombinant Gag pro-
teins purified by affinity chromatography on nickel-
sepharose column.
Screening of Gag-binding ankyrins using the phage-
display method
The phage-displayed library of ankyrins was amplified
using a conventional protocol [34,35], and Gag-binders
Table 1 Randomization schemes used to introduce variability at specific positions of ankyrin repeats
(a)
Repeat position Degenerated codons Subset of encoded amino acid
2 VDK, DMY, RAA A, D, E, G, H, I, K, L, M, N, Q, R, S, T, V, Y
3 VDK, DMY, VAN A, D, E, G, H, I, K, L, M, N, Q, R, S, T, V, Y
5 VDK, DMY, VAN, TGG A, D, E, G, H, I, K, L, M, N, Q, R, S, T, V, W, Y
10 CTG, TGG, TAC, RTC I, L, V, W, Y
13 KCK, TAC, CGY, VAR A, E, F, I, K, L, M, Q, R, S, Y
14 KCK, VAR, AAC, SGY, YAY, NTG A, E, G, H, K, L, M, N, Q, R, S, V, Y
(a) For each position indicated on the leftmost column, the degenerated codons used for the microgene synthesis and the corresponding encoded amino-acids
are indicated in the middle and rightmost columns, respectively. Standard letter for mixed bases refer to: N = A/T/G/C, V = A/C/G, D = A/G/T, K = G/T, M = A/C, Y
= C/T, R = A/G.
Table 2 Amino acid and nucleotides sequences of the ankyrin-repeat microgenes
Repeat
position
1 5 10 15 20 25 30
A D×XG×TPLHLAA×XGHLEIEVLLLK×GADVNAX
BD × X G × T P L H X AA×XGHLEIVRLLLEHGADVNAR
C gac xxx xxx ggt xxx acc ccg ctg cac xxx gct gcg xxx xxx ggt cat ctg gaa atc gtt cgt ctc ctg ctg gaa cac ggc gca gac gta aac gcg cgt
D* vdk vdk vdk ctg kck kck
dmy dmy dmy tgg tac var
raa van van tac cgy aac
tgg rtc var sgy
yay
ntg
E ——————————Va ——————®¬ ——Vb——®¬ ————————— Vc ——————————®
¬————————————————————— C1 ———————————————————®¬ -Va—————
–C3- > ¬—————— Vb rev ————®¬ ————————————— C2 ——————————®
¬—————————————— C3 ————————————————————
(A), Amino-acid sequence of the previously described ankyrin-repeat module [23].
(B), Amino-acid sequence of the ankyrin-repeat used in the present study.
(C), Nucleotide sequence of the ankyrin microgenes.
(D), Set of partially randomized codons used at each variegated position is indicated. (*), the full sequence of the set of oligonucleotides will be communicated
upon request.
(E), Position of the different types of oligonucleotides used to synthetized the ankyrins microgenes along the nucleotide sequence.
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Page 3 of 27were isolated by three rounds of selection/elution from
surface-immobilized H6MA-CA protein. Elution of
H6MA-CA-bound phages was performed using acidic
buffer for the first two rounds, followed by specific
ligand elution using excess of soluble H6MA-CA protein
as the competititor in the third round [34,35]. Phage
clones were picked at random in each eluate, and tested
by ELISA for binding to H6MA-CA. Only 20% of Gag-
binders were found in the first eluate, whereas a signifi-
cant enrichment was observed in the second and third
eluates, with 70% of Gag-binders in both. Clones which
gave a signal 5-fold over the background signal were
picked in all eluates and sequenced. All positive clones
showed two or three ankyrin repeats flanked by N-cap
and C-cap. Three different clones, referred to as
Ank
GAG1B8, Ank
GAG1D4 and Ank
GAG6B4 and contain-
ing three ankyrin modules each, were identified several
times; they were therefore selected for further studies.
To evaluate the specificity of our Gag-binders, an irre-
levant target protein, aRep-A3, was used in lieu of
H6MA-CA. Protein aRep-A3, previously described
under the acronym aRep-n4-a in our previous study
[33], is an artificial alpha-helicoidal repeat protein
(aRep) based on thermostable HEAT-like repeats, which
folds cooperatively and shows a high stability [33]. Our
phage-displayed ankyrin library was screened on
Bsm BI  Not I  Hind III  Bsp MI 
T7p         pLac/RBS         DsbA ss        St2       N-cap       Rep cloning sites      C-cap      H6     p3      
(    Ank Repeat    ) n     A  
B 
Ankyrin Repeat  
N-cap 
C-cap 
Rep Cloning sites  
    L   L   E   H   G    A   D    V   N   A   R    D   X    X   G   X   T   P   L    H   X   A    A   X    X   G   H   L   E    I   V   R   L      
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Figure 1 Schematic construction of the ankyrin repeat library using the pHDiEx acceptor vector. (A), The mono-ankyrin microgenes were
polymerized by insertion/ligation to pH. DiEx double digested by Bsm BI and Kpn I. The construction was subsequently digested by Bsp MI and
recircularised by intramolecular ligation. This resulted in the substitution of the region containing the Rep cloning sites by the ankyrin repeats.
The number of repeats differed from one clone to another, and usually ranged from 2 to 6 repeats. (B), Detailed sequences of the different DNA
regions. Abbreviations: T7p, T7 promoter; pLac/RBS, lactose promoter and Ribosome binding site; DsbA ss, DsbA signal sequence; St2, Strep-Tag2
tag; H6, hexa-histidine tag.
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Page 4 of 27               
DARPin : DXXGXTPLHLAAXXGHLEIVEVLLKZGADVNAX 
Library: DXXGXTPLHXAAXXGHLEIVRLLLEHGADVNAR 
A              
B              
C              
1---------10----------20----------30-33
Figure 2 Consensus sequence and three-dimensional model of ankyrin module. (A), Sequence comparison between the consensus DARPin
repeat motif and the repeat motif of our ankyrin library. The red letters refer to the positions of random amino acids, and blue letters represent
the residues which differ from the consensus DARPin sequence. The position of the recognition site for the restriction nuclease Bsm BI is
underlined. (B), Structural model of one single ankyrin repeat motif (or module). (C), Spatial arrangement of three modules belonging to the
same ankyrin linear sequence (triple-repeat motif ankyrin molecule). The fixed structure of the repeat motif is presented as a yellow ribbon. The
variable amino acids on the solvent-exposed surface are shown as stick pattern; their respective number in the linear sequence is indicated in
panel B.
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Page 5 of 27immobilized aRep-A3 protein, and aRep-A3-bound
clones were checked for binding specificity and
sequenced. One ankyrin clone with a high affinity and
specificity for the aRep-A3 target, referred to as
Ank
A32D3, was used as the irrelevant control of H6MA-
CA binders in the rest of the present study.
Gag-ankyrin interaction
Gag- and aRep-A3-binding ankyrins were purified, che-
mically biotinylated, and assayed for their capacity of
binding to their specific target in vitro. Importantly, no
change was detected in the interaction of the three Gag-
binders Ank
GAG1B8, Ank
GAG1D4 and Ank
GAG6B4, and
of control aRep-A3-binder Ank
A32D3, with their
respective substrates, as determined by ELISA (data not
shown). This indicated that biotinylation did not alter
their Gag- or aRep-A3-specific binding activity.
The degree of Gag-specificity of biotinylated
Ank
GAG1B8, Ank
GAG1D4 and Ank
GAG6B4 was evaluated
in the presence of specific or nonspecific competitors,
a n dt e s t e di nE L I S Au s i n gH 6MA-CA-coated wells.
Controls consisted of Ank
A32D3 and aRep-A3-coated
wells. Competitors were (i) the same ankyrin protein in
its non-biotinylated form and (ii) non-biotinylated
aRep-A3 protein. Ank
GAG1B8, Ank
GAG1D4, Ank
GAG6B4
and Ank
A32D3 were all competed with their respective
non-biotinylated versions, while no significant competi-
tion was observed between ankyrins Ank
GAG1B8,
Ank
GAG1D4, Ank
GAG6B4 on one hand, and aRep-A3
protein on the other hand (Figure 3A). Interestingly,
Ank
GAG1D4 showed the highest signal of binding to the
H6MA-CA target, and the highest competition effect
was observed with non-biotinylated Ank
GAG1D4 (Figure
3A).
Identification of the ankyrin binding domain on HIV-1
Gag precursor
The structural domain of Pr55Gag recognized by each
of the three Gag-binders Ank
GAG1B8, Ank
GAG1D4 and
Ank
GAG6B4 was determined by Far Western blot analy-
sis and ELISA. Lysates of H6MA-CA-expressing Sf9
were analyzed by SDS-PAGE, and proteins transferred
to PVDF membranes. Spontaneous cleavage of H6MA-
CA by insect cell proteases resulted in the occurrence of
His-tagged N-terminal domain, H6MA, migrating as the
mature matrix protein of the virion, MAp17 (Figure 3B;
control, rightmost lane). All three Gag-binders,
Ank
GAG1B8, Ank
GAG1D4 and Ank
GAG6B4, reacted with
H6MA-CA on blot, but not with H6MA (Figure 3B).
This indicated that the ankyrin binding site was not
located in the MA domain, but in the CA domain. As
expected, no reaction was obtained with the control
aRep-A3-binder Ank
A32D3 (Figure 3B). The reactivity
towards the CA domain was confirmed by indirect
ELISA, using recombinant H6CA protein immobilized
on nickel-coated wells. Positive signals with the CA pro-
tein were detected with all three Gag-binders, but not
with Ank
A32D3 (Figure 3C). This indicated that the
binding sites of Ank
GAG1B8, Ank
GAG1D4 and
Ank
GAG6B4 on H6MA-CA protein were all situated in
the CA domain.
Biochemical characterization of Gag-binding ankyrins
As shown in Figure 3C, Ank
GAG1B8 reacted with H6CA
with the highest apparent affinity. However, DNA
sequencing showed several nonconservative amino acid
substitutions within the highly structured scaffold
domain of the Ank
GAG1 B 8m o d u l e s ,a sw e l la si n
Ank
GAG6B4. Since these mutations could adversely
affect the ankyrin-repeat motifs, Ank
GAG1B8 and
Ank
GAG6B4 were excluded from our next analyses, and
only Ank
GAG1D4 was selected for further characteriza-
tion. DNA sequencing revealed that Ank
GAG1D4 protein
comprised of three ankyrin modules, each containing
different types of amino acids at the six assigned posi-
tions for variable residues (Figure 4A). The oligo-histi-
dine tag allowed us to purify Ank
GAG1D4 protein to
homogeneity by using a two-step chromatographic pro-
cedure, (i) affinity chromatography (Figure 4B, lane 3),
and (ii) gel filtration (Figure 4B, lane 2). SDS-PAGE ana-
lysis showed that Ank
GAG1D4 migrated with an appar-
ent molecular mass of 16.5 kDa (Figure 4B), consistent
with the theoretical mass 17.9 kDa for a protein of 163
amino acid residues.
Mapping of the Ank
GAG1D4 binding site on the CA
domain
A more refined mapping of the ankyrin binding site on
the CA domain was performed using carboxyterminal
deletion mutants of Gag expressed as recombinant pro-
teins in baculovirus-infected cells. Gagamb276 and
Gagamb241 mutants carried an amber stop codon in
the Pr55Gag sequence at positions 276 and 241, respec-
tively [36]. Both recombinant Gag proteins had in com-
mon the MA domain, plus 110 residues of the CA
domain for Gagamb241, and 145 residues of the CA
domain for Gagamb276 [36]. Ank
GAG1D4 was found to
bind to both C-truncated Gag proteins (Figure 5). This
restricted the Ank
GAG1D4 binding site to the N-term-
inal region of the CA domain spanning residues 1 to
110, corresponding to positions 132-241 in the Pr55Gag
sequence of 500 amino acids.
Gag-binding parameters of Ank
GAG1D4
The specificity and binding parameters of Ank
GAG1D4
to its H6MA-CA substrate were determined by microca-
lorimetry (ITC). Titration of increasing amounts of
Ank
GAG1D4 protein into sample cell containing purified
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Page 6 of 27H6MA-CA protein gave the approximate value of 1 μM
for the dissociation constant (Kd) of the specific reaction
of the binder with its target protein (Figure 6; leftmost
top panel). In control experiments, no interaction was
detected between Ank
GAG1D4 and aRep-A3 (Figure 6;
middle top panel). By comparison, Ank
A32D3 interacted
with its substrate aRep-A3 with a Kd =1 8n M( F i g u r e
6; rightmost top panel).
The stoichiometry (N) of the interacting molecules in
the protein complexes and the number of binding sites
were calculated from the fitting curves of ITC data. The
stoichiometry of protein monomers was found to be N
=0 . 9 1f o rt h ep a i rA n k
GAG1D4/H6MA-CA, and N =
0.62 for the control pair Ank
A32D3/aRep-A3 (Figure 6).
The aRep-A3 protein is known to occur as a homodi-
mer [33], and the experimental value of 0.62 was close
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No inhibitor  
Biotinylated Rep-A3 binder  
Figure 3 Gag-binding activity of artificial ankyrins. (A), Competition ELISA. Samples of biotinylated Gag-binders Ank
GAG1B8, Ank
GAG1D4 and
Ank
GAG6B4, and of control biotinylated aRep-A3-binder Ank
A32D3 were mixed with their corresponding non-biotinylated form (black bars), or
mixed with irrelevant soluble target (grey bars), or mixed with buffer containing no inhibitor (white bars). Mixtures were added to H6MA-CA- or
aRep-A3-coated wells, as indicated at the bottom of the panel. Bound-ankyrins were detected by addition of HRP-conjugated extravidin,
followed by the TMB substrate. (B), Far Western blotting. Lysates of BV-H6MA-CA-infected Sf9 cells were electrophoresed in SDS-gel, proteins
transferred to a PVDF membrane, and membrane cut into strips. Gag-binding activity was determined by incubation of the strips with the
different biotinylated ankyrins Ank
GAG1B8, Ank
GAG1D4, Ank
GAG6B4, and Ank
A32D3, as indicated on top of the strips. On the rightmost strip, the
respective positions of the Gag proteins H6MA-CA and H6MA were determined using anti-histidine tag antibody (arrowheads). (C), Indirect
ELISA.H 6CA was captured on nickel-coated plate, and used as substrate for binding assay of biotinylated ankyrins Ank
GAG1B8, Ank
GAG1D4,
Ank
GAG6B4, and Ank
A32D3. Bound-ankyrins were quantitated as in (A). BG, background signal.
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Lane : 1      2       3     
 AnkGAG1D4 
20 kDa > 
15 kDa > 
Figure 4 Characterization of Ank
GAG1D4. (A), Amino acid sequence of the Ank
GAG1D4 protein, represented by using the single letter code.
The variable residues at the six predefined positions on the ankyrin solvent-exposed surface were highlighted in red. (B), SDS-PAGE analysis of
Ank
GAG1D4. The Ank
GAG1D4 protein was first isolated by affinity chromatography on nickel-column (HisTrap column; lane 3), and further purified
by gel filtration chromatography (Sephadex G-75 column; lane 2). Lane 1, molecular mass markers.
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Figure 5 Mapping of the Ank
GAG-1D4 binding site on HIV-1 Gag CA domain. The binding activity of biotinylated Ank
GAG1D4 protein was
tested in ELISA towards surface-immobilized lysates of mock-infected Sf9 cells, or baculovirus-infected Sf9 cells expressing recombinant H6MA-
CA, H6CA, Gagamb241, or Gagamb276 protein. The quantity of bound Ank
GAG1D4 was assayed by reaction with streptavidin-HRP. Data presented
are from triplicate experiments (m ± SEM).
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gested that one molecule of Ank
A32D3 bound to an
aRep-A3 homodimer to form a ternary Ank
A32D3/
(aRep-A3)2 complex. By contrast, Ank
GAG1D4 bound to
the H6MA-CA monomer in a 1-to-1 binary complex.
Construction of SupT1 cell lines stably expressing Gag-
binding ankyrin proteins
Two pCEP4-based episomal plasmids encoding the
Ank
GAG1D4 protein in its Myr+ and Myr0 versions,
respectively, and fused to His-tagged GFP at the N-ter-
minus (Figure 7A) were transfected into the SupT1
cell line. Clones that stably expressed Ank
GAG1D4-GFP
protein (SupT1/Myr+Ank
GAG1D4-GFP and SupT1/
Myr0Ank
GAG1D4-GFP) were identified by fluorescent
microscopy, isolated and expanded under the hygromy-
cin-B selection. Two control SupT1 cell lines harbor-
ing the pCEP4 plasmids encoding the Myr+ and Myr0
versions of Gag-irrelevant Ank
A32D3-GFP (SupT1/Myr
+Ank
A32D3-GFP and SupT1/Myr0Ank
A32D3-GFP)
were generated in parallel. Confocal microscopy
showed that Myr+Ank
GAG1D4-GFP and Myr
+Ank
A32D3-GFP localized in both the cytoplasm and
the plasma membrane, as expected for N-myristoylated
proteins, whereas Myr0Ank
GAG1D4-GFP and
Myr0Ank
A32D3-GFP showed a diffuse cytoplasmic
fluorescence. Flow cytometry analysis showed that
almost 80% of ankyrin-expressing cells were GFP-posi-
tive, and that Myr+Ank
GAG1D4-GFP or Myr0Ank-
GAG1D4-GFP did not negatively interfere with the
surface expression of CD4 (Figure 7B). The status of
CD4 molecules, the primary receptors of HIV-1, was
important to assess in ankyrin-expressing cells prior to
HIV-1 infection, in order to ensure that SupT1/Myr
+Ank
GAG1D4-GFP and SupT1/Myr0Ank
GAG1D4-GFP
cells could serve as host cells for testing the function-
ality of Ank
GAG1D4 as antiviral agent.
HIV-1 infection of ankyrin-expressing SupT1 cell lines
SupT1/Myr+Ank
GAG1D4-GFP, SupT1/Myr0Ank-
GAG1D4-GFP, SupT1/Myr+Ank
A32D3-GFP and SupT1/
Myr0Ank
A32D3-GFP cells were infected with HIV-
1NL4-3 virus at MOI 10 for 16 h at 37°C. Cells were
harvested at day 11 post-infection (pi), and examined
in confocal microscopy after permeabilization and
reaction with anti-CAp24 mAb and PE-conjugated
anti-mouse IgG-F(ab’)2 antibody. In infected cells
expressing Myr+Ank
GAG1D4-GFP, the Gag and GFP
signals superimposed in both cytoplasmic compart-
ment and at the plasma membrane, as expected for
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Figure 6 Gag-binding activity of Ank
GAG1D4 analyzed by microcalorimetry (ITC): affinity and specificity. The affinity of Ank
GAG1D4
towards its Gag substrate H6MA-CA (leftmost panel) and the affinity of Ank
A32D3 towards its aRep-A3 substrate (rightmost panel) were
determined by ITC measurements of ankyrin/substrate mixtures at various protein ratios. The Gag-binding specificity was evaluated by ITC
analysis of the mixture of Ank
GAG1D4 and irrelevant substrate aRep-A3 at various protein ratios (middle panel). The parameters of each binding
reaction, Kd and stoichiometry (N), are shown under the corresponding panel. NA, calculation not applicable.
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(b) pCEP4-Myr0AnkGAG1D4-GFP   
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Figure 7 Characterization of SupT1 cells stably expressing artificial ankyrins. (A), Ankyrin constructs. Schematic representation of the
artificial ankyrin constructs designed for stable expression in SupT1 cells, using pCEP4-based vector. Histidine-tag and green fluorescence protein
(GFP; green box) were inserted at the C-terminus and in-phase with the ankyrin sequence (white box). Addition of a N-myristoylation signal (in
purple red letters) to the Myr+Ank
GAG1D4-GFP clone resulted in the removal of the N-terminal methionine (M) and covalent linkage of myristic
acid chain (Myr; in blue letters) to glycine-2 (G). (B), Flow cytometry. Expression of CD4 molecules at the surface of control SupT1 cells, SupT1/
Myr+Ank
GAG1D4-GFP and SupT1/Myr0Ank
GAG1D4-GFP cells. Flow cytometry analysis was performed on nonpermeabilized cells, using monoclonal
antibody against CD4, followed by PE-conjugated goat anti-mouse IgG.
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teins (Figure 8a). Gag and Gag-irrelevant N-myristoy-
lated ankyrin Myr+Ank
A32D3-GFP were also both
addressed to the plasma membrane, but showed a les-
ser degree of colocalization (Figure 8c). No significant
colocalization was detected for Gag and the non-N-
myristoylated, Gag-irrelevant ankyrin Myr0Ank
A32D3-
GFP (Figure 8d). Interestingly, a significant degree of
colocalization was observed for Gag and the non-N-
myristoylated Gag-binder Myr0Ank
GAG1D4-GFP (Fig-
ure 8b). This implied that Gag and Myr0Ank
GAG1D4-
GFP proteins interacted within the cytoplasm and were
addressed as a complex to the plasma membrane, via
the N-myristoylated signal carried by the Gag protein
partner.
Negative effect of Ank
GAG1D4 on HIV-1 production
The possible antiviral activity of Ank
GAG1D4 on HIV-1
assembly and budding was first evaluated by syncytium
formation. SupT1 cells expressing Myr+Ank
GAG1D4-
GFP, Myr0Ank
GAG1D4-GFP, Myr+Ank
A32D3-GFP and
Myr0Ank
A32D3-GFP, respectively, were infected with
HIV-1NL4-3 virus at MOI 10 for 16 h at 37°C, and exam-
ined by phase contrast microscopy at day 11 pi. Numer-
ous syncytia were observed in control samples of HIV-
1-infected SupT1 cells (Figure 9, upper row) as well as
in HIV-1-infected SupT1/Myr+Ank
A32D3 and SupT1/
Myr0Ank
A32D3 cells (Figure 9, two bottom rows). How-
ever, very few syncytia were observed in HIV-1-infected
SupT1/Myr0Ank
GAG1D4 cells (Figure 9, third row from
the top), and very rare, if any, in HIV-1-infected SupT1/
(a) HIV-1 : SupT1/Myr+AnkGAG1D4-GFP     
(c) HIV-1 : SupT1/Myr+AnkA32D3-GFP   
R = 0.855  
R = 0.757   
(b)  HIV-1 : SupT1/Myr0AnkGAG1D4-GFP 
R = 0.815  
(d) HIV-1 : SupT1/Myr0AnkA32D3-GFP  
R = 0.115  
Figure 8 Confocal microscopy of HIV-1-infected, ankyrin-expressing SupT1 cells. HIV-1-infected SupT1/Myr+Ank
GAG1D4-GFP (panel a),
SupT1/Myr0Ank
GAG1D4-GFP (b), SupT1/Myr+Ank
A32D3-GFP (c), and SupT1/Myr0Ank
A32D3-GFP cells (d) were collected at day 11 pi,
permeabilized, immunolabeled with anti-CAp24 mAb and PE-conjugated anti-mouse IgG F(ab’)2 antibody (red signal), and nuclei counter-stained
in blue with DAPI. Ankyrins were detected by their GFP-tag. Merged images are enlarged and shown on the right side of each panel. White
arrows point to cells showing colocalization of ankyrin and Gag proteins. R, the Pearson correlation coefficient for signal colocalization, was
determined using the Olympus FluoView software.
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GAG1D4 cells (Figure 9, second row from the
top).
Virus yields were quantitated in the extracellular med-
ium of ankyrin-expressing SupT1 cells infected with
HIV-1NL4-3 virus, in the same conditions as above. Cul-
ture supernatants were collected at different times pi,
and virus progeny titer indirectly determined using
ELISA/CAp24. A significant reduction of extracellular
Control, 
no exogenous 
ankyrin
 Myr0AnkA32D3 
 Myr+AnkA32D3  
 Myr0AnkGAG1D4
 Myr+AnkGAG1D4 
SupT1 cells 
HIV-1
MOI  0 MOI 10
Figure 9 HIV-1-induced syncytium formation.S u p T 1 / M y r + A n k
GAG1D4, SupT1/Myr0Ank
GAG1D4, SupT1/Myr+Ank
A32D3 and SupT1/
Myr0Ank
A32D3 were mock-infected (MOI 0; left column) or infected with HIV-1 (MOI 10, right column). Cells were observed at 400X
magnification using an inverted microscope. Black arrows point to syncytia.
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Page 12 of 27levels of CAp24 was observed at days 11 and 13 pi in
the supernatants of SupT1/Myr+Ank
GAG1D4-GFP and
SupT1/Myr0Ank
GAG1D4-GFP cells, compared to con-
trol cells, nontransduced HIV-1-infected SupT1 cells
and SupT1 cells expressing the Gag-irrelevant ankyrin
Myr+Ank
A32D3-GFP (Figure 10A). There was a slight
decrease of CAp24 levels in the culture medium of
SupT1/Myr+Ank
A32D3-GFP, compared to control
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Figure 10 Ank
GAG1D4-mediated inhibitory effect on HIV-1 replication. (A), CAp24 titration.S u p T 1 / M y r + A n k
GAG1D4 and SupT1/
Myr0Ank
GAG1D4 stably expressed the N-myristoylation and non-N-myristoylation versions of the H6MA-CA-binding ankiryn Ank
GAG1D4,
respectively. SupT1/Myr+Ank
A32D3 and SupT1/Myr0Ank
A32D3 expressed the N-myristoylation and non-N-myristoylation versions of the aRep-A3-
binding ankyrin Ank
A32D3, respectively. Cells were infected with HIV-1 NL4-3 at MOI 10, and cell culture supernatants collected at time intervals (5,
7, 9, and 11 days pi) and virus progeny titers determined by CAp24 assays, using ELISA. Results shown are mean (m) from triplicate experiments
± SEM. (B), Viral load. The copy numbers of viral genome were determined in the culture supernatants collected on day-11, using Cobas
Amplicor tests. Data presented are from triplicate experiments (m ± SEM). The average values were the following: Control SupT1 cells = 2, 470 ×
10
7 copies/mL; SupT1/Myr+Ank
GAG1 D 4=4×1 0
7; SupT1/Myr0Ank
GAG1D4 = 15 × 10
7 ; SupT1/Myr+Ank
A32D3 = 140 × 10
7 ; SupT1/Myr0Ank
A32D3
= 245 × 10
7.
Nangola et al. Retrovirology 2012, 9:17
http://www.retrovirology.com/content/9/1/17
Page 13 of 27SupT1 cells, and this effect was less pronounced in
SupT1/Myr0Ank
A32D3-GFP cells, which expressed a
Gag-irrelevant, non-N-myristoylated ankyrin, (Figure
10A). The possibility that the increase in CAp24 yields
at day 13 pi might be due to Ank
GAG1D4-escape HIV-1
mutant(s) was investigated: no mutation in the gag gene
was found in RT-PCR amplicons derived from the HIV-
1 progeny of SupT1/Myr+Ank
GAG1D4 cells harvested at
day 13. However, this did not exclude that Ank
GAG1D4-
resistant gag mutants could be found after a higher
number of passages. Long-term cultures of HIV-1-
infected SupT1 cells stably expressing Ank
GAG1D4 will
be necessary to evaluate the viral genetic barrier to
Ank
GAG1D4.
Viral loads were also determined at day-11 in the
extracellular media, and the data confirmed the ELISA/
CAp24. A significant inhibitory effect of Myr
+Ank
GAG1D4 on HIV-1 replication was observed, with
an average 600-fold lower virus progeny production,
compared to control, nontransduced HIV-1-infected
SupT1 cells (2, 500 × 10
7 genome copies/mL; Figure
10B). A significant decrease in HIV-1 production was
also observed with the non-N-myristoylated ankyrin
Myr0Ank
GAG1D4, although to a lesser degree compared
to its N-myristoylated version (160-fold less; Figure
10B). These results indicated that the antiviral function
of Ank
GAG1D4 occurred in both compartments, plasma
membrane and cytoplasm, but with a higher efficiency
when the ankyrin molecules were addressed to the
plasma membrane (Figure 10B). This suggested that the
antiviral function carried by Ank
GAG1D4 occurred at
late step(s) of the virus life cycle, e.g. the assembly and
budding of virus particles. As observed in ELISA/
CAp24, SupT1 cells expressing Gag-irrelevant, N-myris-
toylated ankyrin molecule Myr+Ank
A32D3-GFP showed
some decrease (17-fold) in virus production (140 × 10
7
genome copies/mL; Figure 10B).
Ank
GAG1D4-mediated antiviral activity in HIV-1 life cycle:
early versus late step(s)
A sap a r t n e ro ft h eH I V - 1s t ructural protein CAp24,
Ank
GAG1D4 might interfere with various step(s) of the
HIV-1 life cycle. This included (i) virus uncoating, (ii)
intracellular trafficking of incoming viruses, (iii) nuclear
import of the viral preintegration complex, at early
times, (iv) Gag oligomerisation, (v) virus particle
assembly, and (v) extracellular budding, at late times
post infection. To address this issue, integration events
were evaluated by PCR amplification of Alu-gag junc-
tions in HIV-1-infected, Ank
GAG1D4-expressing SupT1
cells harvested at day 11 pi. Control samples consisted
of HIV-1-infected, nontransfected SupT1 cells and
SupT1 cells expressing Gag-irrelevant, Ank
A32D3
ankyrin. There was no significant difference between
Ank
GAG1D4-expressing SupT1 cells and control cells
(Table 3), suggesting that the Ank
GAG1D4-mediated
antiviral effect took place at the post-integration phase
of the virus life cycle. To validate this negative result,
control experiments of integration blockage were carried
out using the HIV-1 integrase inhibitor Raltegravir™
(RAL). RAL was added at increasing molarities (1, 10
and 100 nM) to the SupT1 cell culture medium 24 h
prior to HIV-1 infection, and maintained for 7 days
[37]. No significant alteration of the cell viability was
observed within this molarity range (Additional File 1).
No viral integration was detectable at RAL molarities
over 10 nM (Table 4 and Additional File 1), a result
which was consistent with the IC50 value of 10 nM for
RAL [37].
To further dissect the nature of the post-integration
blockage of HIV-1 provoked by Ank
GAG1D4, the fate of
the viral target of Ank
GAG1D4, the Gag protein, was
analyzed in HIV-1-infected SupT1 cells harvested at late
times pi and subjected to cell fractionation. Whole cell
lysates and cell fractions were assayed for Gag content
by ELISA/CAp24, and the Gag protein pattern analysed
by SDS-PAGE and Western blotting. The CAp24 levels
were significantly lower in Myr+Ank
GAG1D4- and
Myr0Ank
GAG1D4-expressing cells, compared to control
cells expressing no exogenous ankyrin or the Gag-irrele-
vant ankyrin Ank
A32D3 (Figure 11). A similar decrease
was observed in the whole cell lysate and membrane
fraction (Figure 11, compare panels A and B), implying
that the antiviral effect of Ank
GAG1D4 did not involve
the trafficking of Gag to the plasma membrane.
Western blot analysis showed a drastic reduction of all
Gag protein species in Myr+Ank
GAG1D4- and Myr0-
Ank
GAG1D4-expressing cells compared to control cells
(Figure 11C, D). This pattern excluded a possible inter-
ference of Ank
GAG1D4 with the proteolytic processing
of Gag, which might provoke a premature cleavage of
the Pr55Gag precursor.
Table 3 HIV-1 integration events in control and ankyrin-expressing SupT1 cells
(a)
Sequence
amplified
No ankyrin Myr+Ank
GAG1D4 Myr0Ank
GAG1D4 Myr+Ank
A32D3
Alu-gag junctions 28.3 ± 0.2 28.6 ± 0.3 30.5 ± 0.1 27.8 ± 0.2
GAPDH 25.7 ± 0.4 26.1 ± 0.5 25.5 ± 0.5 24.5 ± 0.1
(a) The level of HIV-1 integration in SupT1 cells harvested at day 11 pi was evaluated by quantitative PCR amplification of host cell DNA extracts, using primers
specific to Alu-gag junctions, and to cellular GAPDH gene used as the internal control. Figures shown in the Table are Cts values, mean ± SD (n = 3).
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GAG1D4
The viral specificity of Ank
GAG1D4 was evaluated on
HIV-Luc and Moloney murine leukemia virus (MLV)-
Luc vectors, which express the luciferase-encoding
reporter gene. HIV-Luc was produced in 293T cells, and
MLV-Luc was produced in the GP2-293-Luc packaging
cells, which stably express the MLV gag-pol gene pro-
ducts and a packageable, luciferase-encoding MLV RNA
transcript [38]. HIV-Luc and MLV-Luc producer cells
were transfected by the different pCEP4-ankyrin plas-
mids, and the extracellular media were collected at 72h
posttransfection and assayed for vector yields. Vector
titers were determined by measuring the luciferase activ-
ity in HIV-Luc- and MLV-Luc-infected 293T cells [39].
The expression of Myr+Ank
GAG1D4 and Myr0Ank-
GAG1D4 in vector producer cells resulted in a 20-fold
lower production of HIV-Luc (Figure 12A), while MLV-
Luc production was decreased by 6- to 8-fold (Figure
12B). These results suggested a significant degree of
Ank
GAG1D4 cross-reactivity between HIV-1 and MLV,
two evolutionarily divergent retroviruses. Of note, the
expression of non-relevant ankyrins Myr+Ank
A32D3
and Myr0Ank
A32D3 decreased both HIV-Luc and MLV-
Luc yields by a factor of 2, indicative of a basal interfer-
ence level for ankyrins (Figure 12A, B).
Discussion
Although HAART can significantly reduce HIV-1 repli-
cation and prolong the life of HIV-infected individuals
[1,10], the treatment is lifelong, causes a variety of side-
effects with cumulative toxicities, and is responsible for
the development of resistant viral strains [40]. Moreover,
host genome-integrated proviral DNA persists in latent
tissue reservoirs in HIV-1-infected individuals [1,10]. All
these disadvantages have led many laboratories to con-
sider the use of anti-HIV gene therapy, either as a
stand-alone approach, or as an adjuvant to pharmacolo-
gical regimens [10,41]. Gene therapy offers the potential
of preventing progressive HIV infection by a sustained
interference with the intracellular cascade that leads to
virus replication. The aim of the present study was to
investigate a novel class of intracellular protein-based
antiviral agents, which would interact with viral proteins
at critical steps of the virus life cycle and act as intracel-
lular inhibitors of viral replication. One particular HIV-1
protein target which still lacks specific inhibitor(s) at the
stage of clinical development is the Gag polyprotein pre-
cursor Pr55Gag and the late step of viral assembly
[41-49]. The viral protein that we used as the target in
this study was a truncated form of Gag precursor, con-
sisting of the MAp17 and CAp24 domains (MA-CA),
with ankyrin-derived repeat proteins acting as intracellu-
lar interactors and potential blockers.
Ankyrin-repeat proteins or DARPins represent poten-
tial candidates of anti-HIV-1 molecules, since they are
considered as the best alternative to intracellular antibo-
dies, single chain antibodies or intrabodies, in terms of
binding affinity, specificity and stability
[12-14,23,26,27,30]. The molecular architecture of
ankyrin-derived repeat proteins consists of a common
structural framework made of a theoretically unlimited
number of helix-turn-helix repeat motifs or modules,
arranged in a parallel orientation. The same positions in
consecutive repeats can accommodate variable amino
acid residues, selected randomly, with the exclusion of
cysteine, glycine and proline [23]. All variable amino
acid side chains are oriented on the same side of the
helices (refer to Figure 2B), and are presented on a large
solvent-accessible, hyper-variable surface which is well
adapted to bind large surfaces on desired targets [22].
More importantly, the correct folding and stability of
these molecules do not depend on disulfide bridge for-
mation and can therefore occur in all environments,
including extracellular and intracellular milieu, which is
a major advantage over antibodies [26,27,30]. The num-
ber of modules is theoretically unlimited, and highly
variable, in natural ankyrins, but the number of ankyrin
modules in selected binders is generally restricted to
two or three, although longer proteins up to fifteen
modules are also present in libraries [23]. This is not
due to a better functional adaptation of shorter ankyrins,
but likely to the proportion of coding sequences in short
versus longer proteins. Long ankyrin constructs are
more likely to incorporate at least one frameshift muta-
tion; thus the useful diversity of longer sequences is lim-
ited. Nevertheless, arrangements of two to three
modules have enough surface and variability to generate
binders with high affinity and specificity.
The construction of a DARPin library with random
amino acids at predetermined, surface exposed positions
in the conserved alpha-helical module of ankyrin
required the use of oligonucleotides synthesized from
trinucleotide synthons. This constituted the major
obstacle in the construction of such libraries, since this
Table 4 HIV-1 integration events in control and
Raltegravir-treated SupT1 cells
(a)
Sequence
amplified
Raltegravir (nM)
0 1 10 100
Alu-gag junctions 26.9 ± 0.2 36.1 ± 0.3 ND ND
GAPDH 23.3 ± 0.5 23.7 ± 0.4 24.1 ± 0.3 23.9 ± 0.2
(a) Aliquots of HIV-1-infected SupT1 cells were pretreated with Raltegravir at 0,
1, 10, and 100 nM, respectively, for 24 hr prior to HIV-1 infection (MOI 10),
and the drug maintained at the indicated concentrations for 7 days. Host cell
genomic DNA was extracted on day 7 pi, and the level of HIV-1 integration in
SupT1 cell lines was evaluated by quantitative PCR amplification of DNA
extracts, using primers specific to Alu-gag junctions and to cellular GAPDH
gene as the internal control. Figures shown in the Table are Cts values (mean
±S D ,n = 3). ND, not detectable (below the threshold of detection).
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Page 15 of 27technology is not commonly accessible. To overcome
this inconvenience, we developed an alternative strategy
based on a mixture of partially degenerated oligonucleo-
tides and generated a phage-displayed ankyrin-repeat
library with a reasonable degree of diversity. What is
referred to as ‘useful diversity’ of the ankyrin library
generated in this study was estimated to be 6 × 10
7
independent coding sequences.
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Figure 11 Effect of ankyrin expression on Gag protein levels in HIV-1-infected SupT1 cells. Control and ankyrin-expressing SupT1 cell lines
were infected with HIV-1NL4-3 inoculum at 10 MOI for 16 h at 37°C. After washing with serum-free medium, cells were resuspended in
prewarmed medium containing 500 μg/mL hygromycin B and 10% FCS, and seeded into 6-well plates. Cells were harvested and lysed at day 9
and 11 pi. Cell lysates were fractionated into nuclear pellet, membrane compartment and cytosol, and each fraction assayed for CAp24 content
by ELISA, and Gag proteins by SDS-PAGE and Western blot (WB) analysis. Protein concentration in all samples was normalized to 10 μg/mL. (A),
ELISA of whole cell lysates (WCL); (B), ELISA of membrane/particulate fractions. Data presented are mean from triplicate experiments, with error
bars indicating the standard error to mean. (C, D), SDS-PAGE and WB analysis of WCL. Samples were taken at day 11 pi, and analyzed using anti-
CAp24 (C) and anti-MAp17 mAb (D).
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Figure 12 Influence of Ank
GAG1D4 on the HIV-Luc (A) and MLV-Luc vector (B) yields. VSV-G-pseudotyped HIV-Luc released by 293T cells
cotransfected with pNL4-3Luc(R-E-), phCMV-G and pCEP4-ankyrin (A), and VSV-G-pseudotyped MLV-Luc vector released by GP2-293-Luc cells
cotransfected with phCMV-G and pCEP4-ankyrin (B), were titrated on 293T cells, using the luciferase assay. RLU, relative light units. Data shown
are m ± SEM, n =3 .
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CA domains of HIV-1 Gag used as the bait, we isolated
Ank
GAG1D4, a Gag-specific, trimodular ankyrin with an
apparent molecular mass of 16.5 kDa. The potential
capacity of Ank
GAG1D4 to interfere with HIV-1 replica-
tion was evaluated in SupT1 cells expressing the N-myr-
istoylated (SupT1/Myr+Ank
GAG1D4) and the non-N-
myristoylated (SupT1/Myr0Ank
GAG1D4) versions of
Ank
GAG1D4, respectively. We observed a lower permis-
siveness to HIV-1 for both cell lines, with a significant
reduction of the HIV-1 progeny released in the culture
medium, compared to control cells expressing Gag-irre-
levant ankyrins or no exogenous ankyrin. The
Ank
GAG1D4 anti-HIV-1 effect was found to occur at the
post-integration phase of the virus life cycle, a result
consistent with Gag, the viral structural protein being
the target of Ank
GAG1D4. The results obtained with the
MLV-Luc vector indicated that Ank
GAG1D4 could have
antiviral effect on phylogenetically distant retroviruses.
Interestingly, the interferon-induced cellular protein
HERC5, which acts as a host restriction factor of HIV-1
infection, has been found to block both HIV-1 and
MLV Gag particle assembly with a similar efficiency
[50]. The cross-reactivity observed between HIV-1 and
M L Vi m p l i e dt h a tA n k
GAG1D4, which was selected on
HIV-1 Gag, recognized a conformational structure or/
and motif conserved among retroviral Gag
prolyproteins.
The mechanism of Ank
GAG1D4 activity was further
dissected in HIV-1-infected SupT1 cells. No premature
cleavage or sequestration of the Pr55Gag precursor in a
cellular compartment was observed, but a lower Gag
content was found in both Myr+Ank
GAG1D4- and
Myr0Ank
GAG1D4-expressing cells, compared to control
cells. Image analysis of HIV-1-infected, ankyrin-expres-
sing SupT1 cells suggested that the non-N-myristoylated
Myr0Ank
GAG1D4 bound to nascent or newly synthe-
sized Gag polyprotein within the cytoplasm, and that
the Myr0Ank
GAG1D4-Gag complex was addressed to
t h ep l a s m am e m b r a n ev i at h eN - m y r i s t o y l a t i o ns i g n a l
carried by Gag. N-myristoylated Myr+Ank
GAG1D4, how-
ever, was genetically designed for plasma membrane tar-
geting. In both cases, the formation of Ank
GAG1D4-Gag
protein complexes likely resulted in the depletion of
Gag from the pool of molecules available for virus
assembly. Although these results suggested that the spe-
cific interaction of Ank
GAG1D4 with the CA NTD nega-
tively interfered with the Gag assembly and budding
pathway at the plasma membrane, some interference
with the interaction of Gag with the viral genomic RNA
could not be excluded. This early interaction has been
shown to occur at perinuclear/centromal sites [51] and
could be the target of the cytoplasmic Myr0Ank
GAG1D4.
The molecular and cellular mechanism of the
Ank
GAG1D4 antiviral effect might also involve the
plasma membrane anchoring of Gag via its N-myristoy-
lated signal. Several reports have shown a link between
membrane anchoring of the Pr55Gag precursor and its
translation. N-myristoylated Pr55Gag protein regulates
its own translation in vitro i nt h ep r e s e n c eo fp l a s m a
membrane-containing fraction [52,53]. In the present
study, SupT1/Myr+Ank
GAG1D4 cells showed a lower
permissiveness to HIV-1 infection, compared to SupT1/
Myr0Ank
GAG1D4, suggesting that the addressing of
Ank
GAG1D4 to the plasma membrane compartment via
a N-myristoylated signal significantly increased its effi-
ciency as antiviral agent. Furthermore, the plasma mem-
brane-targeted, Gag-irrelevant ankyrin Myr+Ank
A32D3
showed some negative interference with HIV-1 replica-
tion. It might be therefore hypothesized that Myr
+Ank
GAG1D4 and Myr+Ank
A32D3 occupied anchoring
sites in critical domains of the plasma membrane inner
leaflet which were required for the insertion of
Pr55Gag/genomic RNA complex and the initiation of
virus assembly [54-56]. Alternatively, but not exclusively,
Myr+Ank
GAG1D4 and Myr+Ank
A32D3 might compete
with Pr55Gag for N-myristoyl-transferases, resulting in
decreased levels of N-myristoylated Pr55Gag molecules
competent for plasma membrane anchoring, and viral
particle formation and egress. The latter hypothesis is
consistent with a previous report describing the inhibi-
tory effect of competing unsaturated fatty acids on viral
budding [57].
The binding site of Ank
GAG1D4 was mapped to the
N-terminal moiety of the CA domain, within the first
110 residues. HIV-1 CA domain is composed of two
highly structured subdomains, the N-terminal subdo-
main (NTD, 1-145) and the C-terminal subdomain
(CTD, residues 149-219), separated by a flexible hinge
[58-60]. The Ank
GAG1D4 binding site encompassed two
highly accessible and functionally important regions in
the CA NTD: (i) the aminoterminal ß-hairpin, and (ii)
the cyclophilin-A (CypA) loop [58], which contains Pro-
line-90 and Isoleucine-91. Pro-90 is the substrate of the
CypA cis-trans peptidyl-prolyl isomerase, and Pro-90
and Ile-91 are two residues essential for virion incor-
poration of CypA, an HIV-1 infectivity factor [61-63].
Therefore, besides its effect on virus assembly,
Ank
GAG1D4 could also decrease the infectivity of HIV-1
virions, via a blockage of the CypA encapsidation.
Retroviral Gag and GagPol polyproteins are incorpo-
rated into immature virus particles through Gag-Gag
and Gag-GagPol interactions. In this assembly pathway,
Gag dimerization, mediated by Gag-RNA interaction,
represents a critical step [54-56,64-68]. Crystal analysis
of HIV-1 CA has shown that the CTD is involved in the
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interaction of Ank
GAG1D4 with the CA NTD negatively
interfered with the Gag multimerization process, this
would occur via the NTD-NTD hexamerization inter-
face, or the NTD-CTD interface, and not the CTD-CTD
dimerization interface [58]. This differed from other
peptide inhibitors of HIV-1 Gag assembly which have
been shown to target the CTD-CTD interface and block
the CA dimerization [44,46,60]. Analysis of the H6MA-
CA/Ank
GAG1D4 complex suggested a stoichiometry of
1:1 for the pair of reagents, and a moderate affinity of
Ank
GAG1D4 for its H6MA-CA target in vitro. As a com-
parison, the dodecapeptide ITFEDLLDYYGP (abbre-
viated CAI, for capsid assembly inhibitor), isolated by
screening of a phage-displayed peptide library on the
HIV-1 CA domain, has been found to bind to CA with
a Kd of ~ 15 μM, and to inhibit the Gag multimerization
and formation of immature virus particles at an average
50% inhibitory concentration of about 10 μM [44,46].
Conclusions
The present study demonstrated the potential of
ankyrin-repeat proteins as a novel class of intracellular
antivirals. The data obtained with ankyrin Ank
GAG1D4
showed that a significant antiviral effect could be
obtained with an ankyrin molecule targeted to a struc-
tural protein of the HIV-1 virion, which was the CA
domain of the Gag precursor. The Ank
GAG1D4 mole-
cule therefore represents an attractive platform for the
design of more efficient ankyrin-based intracellular inhi-
bitors of HIV-1 which would negatively interfere with
the virus assembly and egress pathway. More generally,
the antiviral activity shown by Ank
GAG1D4 should con-
tribute to promote the use of ankyrin-repeat proteins as
intracellular therapeutic agents against a variety of
pathogens.
Methods
Cells
Human embryonic kidney cells HEK-293T cells were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA), and maintained as monolayers
in Dulbecco’s modified Eagle’s medium (DMEM; Invi-
trogen) supplemented with 10% fetal bovine serum
(FBS; Invitrogen), penicillin (100 U/mL), and streptomy-
cin (100 mg/mL) at 37°C, 5% CO2. GP2-293 and GP2-
293-Luc packaging cells stably expressed the Moloney
murine leukemia virus (MLV) gag-pol gene products,
and GP2-293-Luc contained an additional packageable,
luciferase-encoding viral RNA transcript [38] expressed
from the luciferase reporter vector pLLRN (BD Bios-
ciences Clontech). Spodoptera frugiperda (Sf9) cells were
maintained as monolayers at 28°C in Grace’s insect
medium supplemented with1 0 %f e t a lb o v i n es e r u m
(FBS) and antibiotics (Invitrogen). They were infected
with recombinant baculovirus at a multiplicity of infec-
tion (MOI) ranging from 2 to 10 PFU/cell, as previously
described [71-74]. SupT1 cell lines stably expressing the
ankyrin-repeat proteins were generated using the
pCEP4-based vector (Invitrogen). Transfected SupT1
cells were maintained in complete RPMI containing
hygromycin B (400 μg/mL).
Plasmids and vectors
Plasmid pQE-30 (Qiagen) was used for production of
6xHis-tagged recombinant proteins in bacterial cells.
Plasmid pNL4-3, obtained from the NIH AIDS Research
and Reference Reagent Program (Division of AIDS,
NIAID, NIH), was used as the template for isolation of
the DNA fragments encoding the wild-type HIV-1 MA-
CA and CA domains, and insertion into the pBlueBac4.5
plasmid (Invitrogen). The pBlueBac4.5 transfer vector
was recombined with the genome of Autographa califor-
nica multiple nucleopolyhedrosis virus (AcMNPV), to
generate recombinant baculoviruses AcMNPV-H6MA-
CA and AcMNPV-H6CA were used to produce the
H6MA-CA and H6CA recombinant proteins. The
pCEP4 vector (Invitrogen) was used for constitutive, epi-
somal expression of designed ankyrins from the CMV
promoter in SupT1 cells. VSV-G-pseudotyped HIV-1-
luciferase vector was recovered from the culture super-
natant of 293T cells cotransfected with equal doses of
pCEP4-ankyrin, phCMV-G and pNL4-3Luc(R-E-) plas-
mids (3 μg of each plasmid per 10
6 cell aliquots), as pre-
viously described [39]. VSV-G-pseudotyped MLV-
luciferase vector was recovered from the culture super-
natant of GP2-293-Luc cells cotransfected with equal
doses (3 μg/10
6 cells) of pCEP4-ankyrin and phCMV-G.
Cell culture supernatants containing the VSV-G-pseudo-
typed HIV-1 or MLV vectors (abbreviated HIV-Luc and
MLV-Luc, respectively) were harvested at 72 h post-
transfection, aliquoted and used for infection of 293T
cells. HIV-Luc or MLV-Luc vector titers were deter-
mined at 24 h pi by luciferase assay of 293T cell lysates
[39].
Construction of ankyrin-repeat protein library
The artificial ankyrin library was constructed using a
combined phage display/expression vector based on
pHDiExDsbA-Ank15 [75]. This vector was used for low
level expression of DARPins fused to the M13 g3p trun-
cated protein in phage display experiments. Since this
construction had also a T7 promoter and a suppressible
stop codon between the DARPins and g3p coding
sequences, it could also be used for periplasmic expres-
sion of nonfused DARPins in non supE strains of E. coli
expressing T7 polymerase. DARPins are extremely stable
proteins and are efficiently translocated to periplasmic
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export sequence [76]. For cytoplasmic expression, the
sequence encoding soluble ankyrin proteins were
inserted into the pQE-30 expression vector (Qiagen),
using M15 (pREP4) strain (Qiagen) for expression. Bac-
terial cells XL-1 Blue MRF’ (Stratagene) were used as
host cells for the generation of the library and propaga-
tion of phages displaying the artificial ankyrin-repeat
protein library.
The generation of our artificial ankyrin-repeat proteins
library was based on that of DARPins library previously
described [23], with the following modifications. A lim-
ited number of changes were introduced in the ankyrin-
repeat consensus sequence in order to create a type II
non-palyndromic restriction site Bsm BI within the
ankyrin module. This site was used to produce ankyrin
module-encoding microgenes from circularly amplified
products and for their subsequent directional polymeri-
zation, in order to create the library. The Bsm BI recog-
nition site was introduced by replacing glutamate-21 by
arginine (E21R substitution) and valine-22 by leucine
(V22L), using the appropriaten u c l e o t i d ec h a n g e s .I n
order to minimize possible charge repulsion involving
t h en e w l yi n t r o d u c e dR 2 1 ,ac o m p e n s a t o r yc h a n g ew a s
made, consisting of a K-to-E mutation at position 25,
which introduced a negative charge in the consecutive
turn of the same alpha helix. These modifications were
not expected to interfere with the folding or stability of
the ankyrin module, since these types of amino acid
residues are commonly found at equivalent positions of
natural protein with ankyrin repeats. Furthermore, the
changes that we created were located on the face of the
protein opposite to the binding surface, and therefore
should not interfere with the potential binding activity
of the artificial ankyrins.
Further changes with respect to previously described
libraries were introduced in the design of this library.
The side chain of residue located at position 10 (helix-1)
was oriented toward the binding surface and was there-
fore partially randomized, while position 26 and 33, not
directly located within the binding surface, were kept
constant. In DARPins libraries previously described, the
modification of each variable amino acids of the ankyrin
repeats were essentially performed randomly, with the
exclusion of cysteine (C), glycine (G) and proline (P).
This was made possible by using oligonucleotides
synthesized from trinucleotide synthons. As this tech-
nology is not commonly accessible, we devised an alter-
native strategy based on a mixture of partially
degenerated oligonucleotides, and comprising of the fol-
lowing steps (Figure 1).
(i) The oligonucleotides pools were designed to
exclude undesired cysteine residues and to mimic the
natural residue frequency of residues at each defined
position where amino acid residues could vary, i.e. posi-
tion numbers 2, 3, 5, 10, 13 and 14 (Table 1). The posi-
tion-specific, natural distribution of amino-acids
frequencies were computed from the natural ankyrin
modules collections defined in the Prosite database
(PS50088). The choice for the set of partially degener-
ated codons was in fact a compromise, in order to mini-
mize the numbers of codons (and therefore of
oligonucleotides), while maintaining the side chains
diversity close to the chemical diversity encountered in
natural ankyrin-repeat proteins.
(ii) The repeat sequences were generated by using a
set of oligonucleotides containing a set of partially
degenerated codons. The sequence coding a single
repeat was divided into four fragments (Table 2): Va
(variable fragment a), Vb (variable fragment b), Vc (vari-
able fragment c) and C1 (constant fragment). Each vari-
able fragment was generated by mixing a pool of
oligonucleotides with randomized positions encoded
with different combination of partially degenerated
codons (Table 1).
(iii) All synthetic fragments (Va, Vb, Vc, and C1) were
hybridized with reverse oligonucleotides linkers ("brid-
ging” fragments; Vb-rev, C2, and C3) at equal molarity
by heating at 95°C for 5 min, followed by progressive
refrigeration to 25°C at the rate of 0.1°C/min.
(iv) To generate the circularized template, the hybri-
dized product was ligated by T4 DNA ligase (New Eng-
land Biolabs, NEB), purified using the NucleoSpin
®
Extract II kit (Macherey-Nagel), and used as the tem-
plate for Rolling Circle Amplification (RCA) process,
using the Illustra TempliPhi 100 amplification kit (GE
Healthcare, Bio-Sciences).
(v) The polymerized product was incubated at 65°C
for 15 min and subsequently treated with BsmB I (NEB)
at 55°C for 4 h, resulting in a mixture of mono-repeat
ankyrin microgenes.
(vi) The mixture of generated fragments was subjected
to a hetero-polymerization process for the generation of
repeat protein library, using a procedures adapted from
a previous work on a different type of repeat protein
[33]. In brief, the pool of mono-repeat ankyrin micro-
genes were inserted into and ligated to a specially
designed “acceptor” vector containing the N- and C-cap
of DARPins (Figure 1). This vector was first cleaved
with BsmBIa n dKpn I (Fermentas) to generate the
cohesive ends compatible with ankyrin repeats micro-
genes. The Kpn I cleavage, although not strictly neces-
sary, was used to minimize the vector recircularization
which would compete with ankyrin-repeat polymerisa-
tion. Once ankyrin repeats were ligated with N-Cap,
vector was cleaved with BspM I (NEB) and recircu-
larised by intramolecular ligation. This resulted in the
elimination of the Rep cloning sites regions and its
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between the N- and C-caps. The ligation product was
transfected into electrocompetent XL-1 Blue cells.
Transformed cells were selected on LB agar containing
ampicillin (100 μg/mL). The number of ankyrin repeats
was determined by gel electrophoresis, after digestion of
the vector pool with Not I( N E B )a n dHind III (NEB).
The quality of the ankyrin library, based on the propor-
tion of readthrough clones, was evaluated by CoFi blot
analysis as previously described [33].
Construction of expression vectors
(i) Baculoviral vectors (AcMNPV). The baculovirus
transfer vector encoding His-tagged MA-CA domains of
Gag (H6MA-CA) was generated as described elsewhere
[77]. For production of recombinant His-tagged CAp24
domain of Gag (H6C A ) ,t h eg e n ee n c o d i n gH 6CA was
amplified from the parental vector pNL4-3 by standard
PCR protocol using pair of primers: FWD-p24 Nhe I, 5’-
GAGGAGGAGGTGCTATAGTGCAGAACCTCCAG-3’
and REV-p24 Kpn I, 5’-GAGGAGGAGCTGGTACCT-
TACAAAACTCTTGCTTTATGGCC-3’.T h eP C Rf r a g -
ment was treated with Nhe Ia n dKpn Ia n d
subsequently cloned into the pBlueBac4.5 transfer vec-
tor, resulting in plasmid pBlueBac-H6CA.
(ii) Bacterial cell vectors (pQE-30). Ankyrin genes
encoding H6MA-CA or aRep-A3-binder (aRep- pre-
viously described as aRep-n4-a (pdb-code 3LTJ; [33])
were inserted into the pQE-30 ankyrin acceptor vector,
designed for soluble protein production. The acceptor
vector was constructed by inserting the hybridization
product of two synthetic oligonucleotides, pQE-Ank-
Adapt-Fw (5’-GATCCGCGGCCGCAAACGCGTAAA-
3’)a n dp Q E - A n k - A d a p t - R e( 5 ’-AGCTTT-
TACGCGTTTGCGGCCGCG-3’), into the Bam HI and
Hind III sites of the pQE-30 vector, resulting in the
insertion of a Not I restriction site into pQE-30. Phage-
mid pHDiExDsbA was treated with Not Ia n dHind III,
and the resulting Not I-Hind III fragment was cloned
into the same sites of the pQE-30 acceptor vector. The
resulting pQE-30 vector contained the gene coding for
Gag-binding or aRep-A3-binding ankyrin. All vector
constructs were transfected into E.coli M15[pREP4]
(Qiagen).
(iii) Mammalian cell vectors (pCEP4). Two versions of
ankyrin-coding vectors, pCEP4-Myr
+Ank-GFP and
pCEP4-Myr0Ank-GFP, were constructed. The N-myris-
toylated ankyrin-GFP fusion protein expressed by
pCEP4-Myr
+Ank
GAG1D4-GFP was designed to be direc-
ted to the plasma membrane, whereas the non-N-myris-
toylated ankyrin-GFP fusion protein expressed by
pCEP4-Myr0Ank
GAG1D4-GFP was designed to localize
in the cytoplasm. The DNA encoding the Gag-binders
Ank
GAG1D4 and control Ank
A32D3 were amplified from
their respective pHDiExDsbA-encoding plasmids using
two sets of primer with or without the N-myristoylation
signal at the 5’e n d .T h eg e n ee n c o d i n gt h eg r e e nf l u o r -
escent protein (GFP) was amplified from pTriEx-GFP
[78], using primers of which sequence will be communi-
cated upon request. PCR products encoding
Ank
GAG1D4 or Ank
A32D3 fused to GFP were recom-
bined by overlapping PCR. The PCR products of the
second round were treated with Kpn Ia n dXho I( F e r -
mentas) and cloned into corresponding sites of the
pCEP4 vector. The sequence of Ank
GAG1D4-GFP and
Ank
A32D3-GFP, as well as all our other constructs, was
verified by standard DNA sequencing.
Production of recombinant H6MA-CA and H6CA proteins
in baculovirus-infected cells
Sf9 cells were cotransfected with 10 μge a c ho fp B l u e -
Bac4.5-H6MA-CA (or pBlueBac4.5-H6CA) and Bac-N-
Blue™ DNA, using Cellfectin
® II reagent, using the con-
ditions recommended by the manufacturer (Invitrogen).
The recombinant viruses obtained, BV-H6MA-CA and
BV-H6CA, were isolated using the blue plaque selection
method, and amplified. BV-H6MA-CA- and BV-H6CA-
infected Sf9 cells were harvested at 48 h postinfection
(pi), lysed by freezing and thawing. The cell lysates were
clarified by centrifugation at 15, 000 × g for 30 min at
4°C. The presence of recombinant Gag proteins was
detected by SDS-PAGE and Western blotting. The
nitrocellulose membranes (GE Healthcare Bio-Sciences)
were incubated with blocking solution (5% skimmed
milk in TBS) for 1 h at RT, and Gag proteins detected
using monoclonal anti-His-tag antibody (1:5, 000 dilu-
tion in the blocking solution) for 1 h at RT with slow
rocking. After washing with TBST (TBS containing
0.05% Tween 20), membranes were incubated with
HRP-conjugated goat anti-mouse Ig (1:8, 000 dilution in
blocking solution) for 1 h at RT. After two extra wash-
ing steps, the Gag proteins were visualized using TMB
membrane peroxidase substrate (KPL). His-tagged Gag
proteins were purified from clarified Sf9 cell lysates by
affinity chromatography on HisTrap column, using
ÄKTA prime™ plus (GE Healthcare Bio-Sciences). Pro-
tein concentration was determined using the Bradford
protein assay (Thermo Fisher Scientific Inc.). Purity of
His-tagged Gag proteins was assessed by SDS-PAGE
analysis in 15% acrylamide gel and Coomassie blue
staining [77].
Phage selection
Microtiter plate (NUNC) was coated with 100 μlH 6MA-
CA protein (or aRep-A3 protein) solution at 20 μg/mL
in sterile PBS, overnight at 4°C. Purified aRep-A3 pro-
tein, produced as described [33], was used as a control
for evaluating the quality of our artificial ankyrin library
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washed four times with sterile-filtered TBST. Non-speci-
fic binding was prevented by blocking with sterile-fil-
tered blocking buffer (2% BSA in TBST; 200 μl per well)
for 1 h at RT with shaking at 150 rpm on an Eppendorf
Thermomixer
® (Eppendorf). After a washing step with
TBST, 100 μl of phage suspension, corresponding to
10
11 particles, was added per well. After 1 h incubation
at RT with shaking, plates were washed 20 times with
TBST and 10 times with TBS. Substrate-bound phages
were eluted by postincubation with 100 μlo f0 . 1Mg l y -
cine solution at pH 2.5, for 10 min at RT with shaking,
followed with pH neutralization using 12.5 μl 1 M Tris-
HCl buffer, pH 8. The eluted phages were mixed with 5
ml of XL-1 Blue cell suspension (OD600 0.6-0.8), and
the mixture incubated for 30 min at 37°C. Bacterial cells
were centrifuged at 1, 200 × g for 10 min at 25°C, pellet
resuspended in 1 ml 2X YT broth and plated on LB
agar containing ampicillin (100 μg/mL). Bacterial colo-
nies were pooled, and used for phage preparation to
perform the next round of phage selection. Individually
picked, single colonies of the second and third rounds
of selection were screened by phage ELISA.
Expression and purification of soluble ankyrins with Gag-
binding activity
M15[pREP4] bacterial cells harboring the pQE30-
ankyrin plasmid were grown in 500 ml LB broth supple-
mented with ampicillin (100 μg/mL), kanamycin (25 μg/
mL), and 1% (w/v) glucose, at 37°C with shaking until
OD600 reached 0.8. Protein expression was induced by
addition of 1 mM IPTG, and maintained in culture for
4 hr at 30°C with shaking. Bacteria were pelleted by cen-
trifugation at 1, 200 × g for 30 min at 4°C. Pellets were
resuspended in lysis buffer and subjected to three cycles
of freezing and thawing. Lysis buffer consisted of TBS
buffer, pH 7.4, containing 1 μg/mL lysozyme and a
cocktail of protease inhibitors (Roche Diagnostics
GmbH). Bacterial cell lysates were clarified by centrifu-
gation at 15, 000 × g for 30 min at 4°C. The soluble
form of Gag-interacting ankyrins was purified from the
clarified bacterial lysates by a two-step procedure com-
prising of affinity chromatography on HisTrap column
followed by gel filtration on Sephadex G-75 (GE Health-
care Bio-Sciences). Proteins were analyzed by SDS-
PAGE and Coomassie blue staining, or SDS-PAGE and
Western blotting, as detailed below.
Biotinylation of soluble ankyrins
Purified Gag-binding ankyrins were chemically biotiny-
lated using the EZ-Link Sulfo-NHS-LC-Biotin kit (Ther-
moScientific, Rockford, IL). In brief, a solution of
purified protein at 100 μM was mixed with a 5-fold
m o l a re x c e s so fS u l f o - N H S - B i o t i ns o l u t i o ni naf i n a l
volume of 2 ml, and incubated at 25°C for 1 h. Excess
reagents and by-products were removed by applying the
mixture to a pre-equilibrated Zeba™ Desalt Spin col-
umn (ThermoScientific). The column was centrifuged at
1, 000 × g for 2 min, and the biotinylated proteins were
recovered in the flow-through fraction. The concentra-
tion of biotinylated proteins was determined using the
NanoDrop 2000 system (ThermoScientific). The biotiny-
lation efficiency of proteins was qualitatively evaluated
using dot-blot analysis. 10 μmol biotinylated proteins
was spotted on nitrocellulose membrane, membrane
blocked with blocking buffer (5% BSA in TBS), and bio-
tin groups revealed by extravidin-HRP (Sigma) used at
dilution 1:5, 000 in blocking buffer (1 h at RT with
shaking) and BM Blue POD Substrate (Roche Diagnos-
tics GmbH).
Assessment of ankyrin reactivity towards HIV-1 MA-CA
polyprotein
(i) Competitive ELISA. Microtiter plates were coated
with 100 μlo fp u r i f i e dH 6MA-CA or aRep-A3 (1 μg/
mL) diluted in PBS and left overnight at 4°C in a moist-
ure chamber. The coated wells were washed four times
with TBST and incubated with 200 μl blocking solution
(2% BSA in TBS) for 1 h at RT. After washing, 100 μl
biotinylated Gag-binding ankyrin at 10 μM, alone or
mixed with an equal molar amount of competitor (non-
biotinylated ankyrin or irrelevant ankyrin), was added
and incubated for 1 h at RT. Plates were then washed
and incubated with extravidin-HRP diluted to 1:5, 000
in blocking solution for 1 h at RT. After washing, 100 μl
of TMB substrate was added, and the reaction was
blocked by addition of 1 N HCl. OD was measured at
450 nm using a MTP-120 ELISA plate reader (Corona
Electric, Ibaraki, Japan).
(ii) Far Western blotting. Lysates of Sf9 cells infected
by BV-H6MA-CA were analyzed by SDS-PAGE and pro-
teins transferred to polyvinylidene fluoride (PVDF)
membrane (GE Healthcare Bio-Sciences). Membranes
were incubated in blocking buffer (5% BSA in TBS)
o v e r n i g h ta t4 ° C ,t h e np o s t i ncubated with biotinylated
Gag-binding ankyrins at 1 μM for 1 h at RT with gentle
rocking. Substrate-bound biotinylated-ankyrins were
detected by reaction with extravidin-HRP (diluted to
1:10, 000 in blocking buffer) and TMB membrane per-
oxidase substrate (KPL).
Mapping of ankyrin binding site on HIV-1 Gag precursor
(i) Specificity assay. The specificity of the Gag-binding
ankyrins towards the CA domain was performed by
indirect ELISA. Lysates of BV-H6CA-infected cells were
added to nickel pre-coated wells, as described elsewhere
[79]. Biotinylated Gag-binding ankyrins were individually
reacted with immobilized H6CA domain for 1 h at 37°C.
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din-HRP (dilution 1:5, 000) and TMB substrate. After
stopping reaction with 1N HCl, the signals were mea-
sured at OD450, as above described.
(ii) Mapping. The ankyrin binding site on the CA
domain was determined using Gag amber mutants
(Gagamb) expressed as recombinant proteins in baculo-
virus-infected cells [36]. Lysates of Sf9 cells expressing
Gagamb276 or Gagamb241 polyprotein were coated on
ELISA plates and reacted with biotinylated Gag-binding
ankyrins, as above.
Microcalorimetry analysis of Gag-ankyrin binding
parameters
Interaction between proteins was analyzed by isothermal
titration calorimetry (ITC), using the MicroCal iTC200
isothermal titration microcalorimeter (Microcal), under
the conditions described in a previous study [80]. All
proteins were diluted in 20 mM phosphate buffer
pH7.5, 150 mM NaCl. For each injection, 2 μlo f
ankyrin solution was added from a computer-controlled
40-μl microsyringe at intervals of 180 s into the protein
substrate solution, H6MA-CA or aRep-A3. A theoretical
titration curve was fitted to the experimental data, as
previously described [80].
Construction of cell lines stably expressing ankyrins
Aliquots of SupT1 cells (10
6 cells) were electroporated
with pCEP4-based vectors encoding GFP-fused ankyrins
with (Myr+) or without (Myr0) the myristoylation signal,
using the Nucleofector™ (Lonza, Basel, Switzerland) and
the Nucleofector™ transfection reagent V (Lonza),
according to protocol T-16. Transfected cells were
maintained in complete RPMI containing hygromycin B
(400 μg/mL). Four cell lines were generated, SupT1/Myr
+Ank
GAG1D4-GFP, SupT1/Myr0Ank
GAG1D4-GFP,
SupT1/Myr+Ank
A32D3-GFP and SupT1/Myr0An-
k
A32D3-GFP, respectively. The level of expression of
Ank
GAG1D4-GFP and control Ank
A32D3-GFP proteins
was monitored by flow cytometry of the GFP signal, and
cellular localization by confocal fluorescence micro-
scopy. For flow cytometry, cells were blocked by incuba-
tion with human AB serum on ice for 30 min. They
were reacted with 50 μl of purified anti-CD4 mAb
M T 4 - 3[ 8 1 ]a t2 0μg/mL in 1% BSA-PBS-NaN3 on ice
for 30 min. At the end of the incubation time, the cells
were washed three times with PBS, and incubated with
25 μl PE-conjugated rabbit anti-mouse F(ab’)2 (DAKO)
on ice for 30 min. Cells were washed, fixed in 1% paraf-
ormaldehyde in PBS, and analyzed by flow cytometry.
HIV-1 challenge
To evaluate the effect of Gag-binding ankyrins on the
HIV-1 life cycle, SupT1 cells stably expressing the Myr
+
or Myr0 version of the best Gag binder Ank
GAG1D4
and irrelevant control Ank
A32D3, were challenged with
HIV-1 virions (NL4-3 strain). Triplicate samples of
SupT1/Myr+Ank
GAG1D4, SupT1/Myr0Ank
GAG1D4,
SupT1/Myr+Ank
A32D3 and SupT1/Myr0Ank
A32D3
were infected at MOI 10 for 16 h at 37°C. The virus
infectivity titer was determined from the genome copy
number measured by quantitative RT-PCR (Roche Diag-
nostics). Cells were then washed three times with
serum-free medium, resuspended in 3 mL of fresh med-
ium containing 400 μg/mL hygromycin B and 10% FCS,
and seeded into 6-well plates. Cells were harvested at
days 5, 7, 9, 11 and 13, and culture supernatants and
cell pellets were separately processed for determination
of virus progeny yields and viral integration.
HIV-1 production assay
The yields of extracellular virus were evaluated in tripli-
cate samples of culture supernatants of day 11 pi, using
a CAp24 ELISA kit (Genscreen ULTRA HIV Ag-Ab,
BioRad). Day-11 samples were also assayed for viral gen-
ome copy numbers, using COBAS
® AmpliPrep/COBAS
TaqMan HIV-1 Test (Roche Diagnostics GmbH). Extra-
cellular budding of virions was also monitored by syncy-
tium formation observed in day-11 samples under an
inverted microscope (Olympus).
Gag protein assays
Membrane-bound and particulate form of Gag proteins
were determined in HIV-1-infected SupT1 cells sub-
jected to cell fractionation. Triplicate cell samples of
days 9 and 11 pi were lysed and extracted using the
FractionPREP™ Cell Fractionation System (BioVision,
Mountain View, CA), following the manufacturer’s
instructions. The membrane fraction thus isolated was
assayed for HIV-1 Gag protein content, using the
CAp24 ELISA kit mentioned above, or SDS-polyacryla-
mide gel electrophoresis (SDS-PAGE) and Western blot-
ting. Proteins were denatured by heating to 100°C for 2
min in SDS-ß-mercaptoethanol-containing sample buf-
fer, electrophoresed in SDS-containing 15%-polyacryla-
mide gel [77], and then electrically transferred to a
polyvinylidene-fluoride (PVDF) membrane. PVDF mem-
branes were blocked with 5% skimmed milk in PBS con-
taining 0.5% Triton X-100, then probed with anti-
CAp24 monoclonal antibody (mAb) G18, or anti-
M A p 1 7m A bM 4 8 .B o t hG 1 8a n dM 4 8m A b sw e r e
laboratory-made (W. Kasinrerk; unpublished). Blots
were developed using HRP-conjugated goat anti-mouse
IgG antibody and TMB membrane peroxidase substrate.
Extracellular virus-like particles (VLP) released by MLV
Gag-Pol-expressing GP2-293 cells were recovered by
ultracentrifugation of the cell culture medium [71,82],
and VLP production estimated by SDS-PAGE of VLP
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antibody to MLV-GagCAp30 protein (antibodies-online
I n c . ,A t l a n t a ,G A ) .I n t r a c e l l u l a rc o n t e n to fM L VG a g
proteins was analyzed in the same manner, using the
whole cell lysate.
HIV-1 integration assay
The number of viral genome copies integrated into the
host DNA of control SupT1 or SupT1 expressing Gag-
specific (Ank
GAG1D4) or irrelevant ankyrin (Ank
A32D3)
was determined using a conventional Alu-gag qPCR
assay [83,84] with some modifications. The first-round
of PCR was performed on cellular DNA, extracted using
the High Pure PCR Template Preparation Kit (Roche,
Mannheim, Germany). The sequences of the first round
amplification primers were: Alu forward, 5’-GCC TCC
CAA AGT GCT GGG ATT ACA G-3’ [84], and HIV-1
gag reverse, 5’- GTT CCT GCT ATG TCA CTT CC -3’
[83]. The first round reactions were carried out in a
volume of 25 μl containing 2.5× master mix (5 PRIME,
Gaithersburg, MD), using a standard protocol. The sec-
ond-round of real-time quantitative PCR of RU5 was
performed using 10 μl of diluted (1:8) first-round ampli-
cons. The sequences of primers were: R_FWD, 5’-TTA
AGC CTC AAT AAA GCT TGC C-3’;a n dU 5_ R E V ,
5’-GTT CGG GCG CCA CTG CTA GA-3’,a n dt h e
sequence of RU5 molecular beacon probe was 5’-FAM-
CCA GAG TCA CAC AAC AGA CGG GCA CA-BBQ-
3’ [85]. The reactions were carried out in a final volume
of 25 μl containing 2× DyNAmo probe qPCR master
mix (Finnzymes, Espoo, Finland), 400 nM RU5
(R_FWD) primer, 400 nM RU5 (U5 _REV) primer, and
140 nM RU5 molecular beacon probe. The reactions
were performed in a MJ Mini Thermal Cycler and Mini-
Opticon Real-Time PCR System (BioRad) with the fol-
lowing thermal program: 20-sec hot start at 95°C
followed by 50 cycles of denaturation at 95°C for 3 sec
and annealing and extension at 63°C for 30 sec. A pri-
mer-probe set, designed to quantify the copy number of
the cellular gene glyceraldehyde 3-phosphate dehydro-
genase (GAPDH), was used to quantify the amount of
DNA in each qPCR assay. The GAPDH primer
sequences were as follows: GAPDH_FWD, 5’-GAA
GGT GAA GGT CGG AGT C-3’; and GAPDH_REV, 5’-
GAA GAT GGT GAT GGG ATT TC-3’.T h e
GAPDHTM molecular beacon probe was designed to
contain the following sequence: 5’-FAM-CAA GCT
TCC CGT TCT CAG CCT-BBQ-3’. The reactions were
carried out as described above. Results were expressed
as Cts, i.e. the number of cycles (Cts) required for the
fluorescence signal to cross the threshold value (cycle
threshold). Control experiments for the inhibition of
provirus integration in HIV-1-infected cells were carried
out as follows. The HIV-1 integrase inhibitor Raltegra-
vir™ (RAL; Merck Sharp & Dohme) was added at 0, 1,
10, and 100 nM, respectively, to SupT1 cell culture
medium 24 h prior to HIV-1 infection [37]. SupT1 cells
were then infected with HIV-1NL4-3 at MOI 10, and
virus inoculum removed after 16 h. Cells were washed
three times with prewarmed, serum-free medium and
resuspended in growth medium containing RAL at the
above-mentioned concentrations. Cells were divided
(1:2) every second day to maintain a cell density of
approximately 10
6 cells per mL, and harvested at day-7
pi for Alu-gag and GAPDH qPCR assays. Cell viability in
each sample was assayed using PrestoBlue Cell Viability
Reagent (Invitrogen).
HIV-1 gag gene sequencing
Mock-infected or HIV-1-infected SupT1 cells (MOI 10)
expressing Myr+Ank
GAG1D4 or Myr+Ank
A32D3, were
harvested at day-13 pi. A four-step protocol was then
applied. (i) Total viral RNA was isolated, using the High
Pure Viral RNA kit (Roche Applied Science, Roche,
Mannheim, Germany). (ii) The viral RNA thus obtained
was reverse transcribed into cDNA, using the Transcrip-
tor High Fidelity cDNA Synthesis Kit with anchored-
oligo(dT)18 primer (Roche). (iii) The single-stranded
cDNA was then amplified, using a proof-reading PCR
protocol (Phusion™ High-Fidelity DNA Polymerase;
Finnzymes, Espoo, Finland) and the following pair of
p24-specific gene primers: FWD_p24 Nhe I, 5’-GAG-
GAGGAGGTGCTAGCCCTATAGTGCAGAACCTC-
CAG-3’ and REV_p24 Kpn I, 5’-
GAGGAGGAGCTGGTACCTTACAAAACTCTTGC
TTTATGGCC-3’. (iv) The PCR products were purified
using the GeneJET™ PCR purification kit (Fermentas
International), and sequenced using standard DNA
sequencing method (1st BASE Pte Ltd, Singapore).
Confocal microscopy
Aliquots of HIV-1-infected SupT1 cells (1 × 10
6 cells,
MOI 10) were harvested on day 11 pi, washed with PBS,
fixed in 4% formaldehyde in PBS, and permeabilized
with 0.2% Triton X-100. After blocking with 10%
human AB serum for 30 min at room temperature, cells
were incubated with G18 anti-CAp24 mAb at 37°C for 1
hr. After washing twice with PBS containing 1% BSA
and NaN3, cells were incubated with PE-conjugated
polyclonal rabbit anti-mouse IgG F(ab’)2 (Dako, Den-
mark), and nuclei counterstained with DAPI. Images
were acquired using FluoView laser scanning confocal
microscope (Olympus, FV1000; Olympus Optical,
Japan).
Additional material
Additional file 1: Control, Raltegravir-mediated inhibition of HIV-1
integration in SupT-1 cells. Aliquots of HIV-1-infected SupT1 cells were
pretreated with Raltegravir at 0, 1, 10, and 100 nM, respectively, for 24 h
prior to HIV-1 infection (MOI 10). The drug was maintained at the
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The level of HIV-1 integration in SupT1 cell lines was evaluated by
quantitative PCR amplification of host cell DNA extracts, using primers
specific to Alu-gag junctions and to cellular GAPDH gene as the internal
control. (A), Alu-gag qPCR obtained with the different cell samples. The
qPCR assays were performed in triplicate. The colours of the curves
correspond to the different Raltegravir molarities, as indicated in (B). (B),
Comparison of the mean Cts values (m ± SD) for Alu-gag and GAPDH
qPCR. ND, not detectable (below the detection threshold). (C), Cell
viability, determined by the PrestoBlue Cell Viability Reagent, and
expressed as the percentage of control, untreated cells.
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